Key Takeaway: Altimmune announced its financial results for Q2 2026, highlighting significant progress in its clinical trials. The company initiated the global PERFORMA Phase 3 trial for MASH and reported positive topline data from the RECLAIM Phase 2 trial in AUD. Additionally, patient enrollment in the RESTORE Phase 2 trial for ALD has been completed, with a strong cash position of $519 million.
Market Sentiment Analysis
POSITIVE FACTORS
Initiated global PERFORMA Phase 3 trial in MASH.
Reported positive topline data from RECLAIM Phase 2 trial in AUD.
Completed patient enrollment in RESTORE Phase 2 trial in ALD.
$519 million in cash and investments as of June 30, 2026.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Pemvidutide
Phase 2 · Non-Alcoholic Steatohepatitis (NASH)
Full Press Release Details
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m.
Frequently Asked Questions
What trials did Altimmune initiate recently?
Altimmune initiated the global PERFORMA Phase 3 trial in MASH.
What were the results from the RECLAIM trial?
The RECLAIM Phase 2 trial in AUD reported positive topline data.
How much cash does Altimmune have as of June 30, 2026?
Altimmune has $519 million in cash, cash equivalents, and investments.
What is the status of the RESTORE trial?
Patient enrollment in the RESTORE Phase 2 trial in ALD has been completed.